Wang Hua, Li Pengfei, Wang Liang, Xia Zhongjun, Huang HuiQiang, Lu Yue, Li ZhiMing
Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, 651 Dong Feng RD East, Guangzhou, 510060, China.
Ann Hematol. 2015 Sep;94(9):1535-44. doi: 10.1007/s00277-015-2401-4. Epub 2015 May 21.
Many studies have demonstrated that tumor-associated macrophages (TAMs) were a prognostic indicator in patients with B cell lymphoma. But, we know little about the clinical significance of TAMs in extranodal natural killer/T cell lymphoma(ENKTL), nasal type. CD68 expression was detected using immunohistochemistry to determine the numbers of TAMs in 70 ENKTL patients, and the data were used to evaluate its relationship with clinicopathological features, treatment response, and prognosis. Patients with high number of infiltrated CD68+ TAMs (>60/hpf) at diagnosis tended to have more adverse clinical characteristics. Patients with low CD68+ TAM content (<60/hpf) at diagnosis had better overall survival (P = 0.003) and progression-free survival (P = 0.002) and achieved higher complete remission rates (P = 0.008). Multivariate analysis revealed that CD68 + TAM content, Ki-67 index, and stage III and IV were independent prognostic factors for both OS and PFS. Using the International Prognostic Index or Korean Prognostic Index for extranodal NK/T cell lymphoma, nasal type, the majority of patients were in the low-risk category. CD68 + TAM content was helpful to differentiate the low-risk patients with different survival outcomes. Our data suggest that CD68+ TAM content at diagnosis is a powerful predictor of prognosis for ENKTL, which suggests a role for TAMs in the pathogenesis of this disease and offers new insight into potential therapeutic strategies.
许多研究表明,肿瘤相关巨噬细胞(TAM)是B细胞淋巴瘤患者的预后指标。但是,我们对鼻型结外自然杀伤/T细胞淋巴瘤(ENKTL)中TAM的临床意义知之甚少。采用免疫组织化学检测CD68表达,以确定70例ENKTL患者的TAM数量,并将数据用于评估其与临床病理特征、治疗反应和预后的关系。诊断时浸润的CD68+ TAM数量较多(>60/hpf)的患者往往具有更多不良临床特征。诊断时CD68+ TAM含量较低(<60/hpf)的患者总生存期(P = 0.003)和无进展生存期(P = 0.002)更好,完全缓解率更高(P = 0.008)。多因素分析显示,CD68+ TAM含量、Ki-67指数以及III期和IV期是总生存期和无进展生存期的独立预后因素。使用国际预后指数或鼻型结外NK/T细胞淋巴瘤的韩国预后指数,大多数患者属于低风险类别。CD68+ TAM含量有助于区分具有不同生存结果的低风险患者。我们的数据表明,诊断时CD68+ TAM含量是ENKTL预后的有力预测指标,这表明TAM在该疾病的发病机制中起作用,并为潜在治疗策略提供了新的见解。